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1. Introduction 
Polymyositis and dermatomyositis (PM-DM) are forms of idiopathic inflammatory myositis 
(Bohan & Peter, 1975, Dalakas & Hohlfeld, 2003). The diagnosis of DM is definite if the 
myopathy is accompanied by the characteristic rash and histopathology. If patients with 
DM has the typical rashes but little (hypomyopathic DM) or no (amyopathic DM) evidence 
of myositis for 6 months or longer, the condition is termed "clinically amyopathic DM" 
(Euwer & Sontheimer, 1991, Gerami et al., 2006). Although muscle strength is apparently 
normal, many patients with clinically amyopathic dermatomyositis have some evidence of 
muscle inflammation upon testing. Some clinically amyopathic dermatomyositis patients 
also have been observed to develop overt proximal muscle weakness years after onset of 
their DM skin disease. Among patients with DM or PM, interstitial lung disease is a major 
cause of morbidity and mortality (Fathi et al., 2008, Love et al., 1991, Marie et al., 2002). In 
particular, patients with clinically amyopathic dermatomyositis sometimes develop rapidly 
progressive interstitial lung disease that remains unresponsive to intensive 
immunosuppresive therapy (Mukae et al., 2009). 
2. Polymyositis and dermatomyositis 
2.1 Diagnostic criteria 
Three sets of classification criteria have been developed for DM-PM. The original criteria 
formulated in 1975 by Bohan and Peter included the following features: symmetric proximal 
muscle weakness, characteristic electromyographic changes, elevation of serum levels of 
muscle-associated enzymes, evidence of chronic inflammation in muscle biopsy, and 
characteristic rashes of DM (Bohan & Peter, 1975). However, when these criteria were 
formulated, testing for myositis-specific autoantibodies was not available. In addition, 
inclusion body myositis was not recognized until the 1980s (Griggs et al., 1995). Thus, 
patients classified as DM or PM according to these criteria may have some other disorder. 
To address this problem, two alternative criteria have been suggested since 2004 
(Hoogendijk et al., 2004, Troyanov et al., 2005). One criterion classifies patients according to 
a "clinicoserologic" approach relying on extensive testing for autoantibodies. Excluding 
inclusion body myositis, four categories of inflammatory myopathy were recognized: pure 
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PM, pure DM, overlap myositis, and cancer-associated myositis (Troyanov et al., 2005). The 
second criterion has nine categories based on clinical, histopathologic, and laboratory 
findings with autoantibody tests, which include amyopathic DM also called 
dermatomyositis sine myositis (Hoogendijk et al., 2004). 
2.2 Clinically amyopathic dermatomyositis 
Clinically amyopathic dermatomyositis is an umbrella designation used to refer to DM with 
no myositis (amyopathic DM) or DM with little myositis (hypomyopathic DM), i.e. clinically 
amyopathic DM = amyopathic DM + hypomyopathic DM. Patients with amyopathic DM 
have hallmark inflammatory skin changes of DM but no clinical evidence of proximal 
muscle weakness and no serum muscle enzyme abnormalities for 6 months or longer. If 
more extensive muscle testing is carried out, the results should be within normal limits. 
While, hypomyopathic DM is a condition of cutaneous DM and no clinical evidence of 
muscle weakness. Although muscle strength is apparently normal, patients with 
hypomyopathic DM have some evidence of muscle inflammation on laboratory (eg, muscle 
enzyme elevations), electrophysiologic, and/or radiologic evaluation. Hypomyopathic DM 
could also be classified into 2 groups according to degree of skeletal muscle involvement: no 
subjective muscle weakness but abnormalities detected by objective tests and subjective 
muscle weakness but no objective evidence of myopathy (el-Azhary & Pakzad, 2002). Some 
patients with clinically amyopathic dermatomyositis eventually develop overt proximal 
muscle weakness years after onset of their skin disease; however, muscle involvement may 
not be seen as long as six years after disease onset (Euwer & Sontheimer, 1991, Gerami et al., 
2006, Stonecipher et al., 1993). 
3. Interstitial lung disease associated with polymyositis and dermatomyositis 
3.1 Clinical manifestations 
Pulmonary involvement in PM-DM includes respiratory muscle weakness, aspiration 
pneumonia, infection, drug-induced pneumonia, and interstitial lung disease (Miller, 2004). 
interstitial lung disease occurs approximately 40 percent of patients with PM-DM. It is 
increasingly recognized as a serious complication and a major cause of death in this disease 
(Douglas et al., 2001, Fathi et al., 2008, Marie et al., 2002). High-resolution computerized 
tomography in combination with pulmonary function tests provides sensitive tools to detect 
early signs of intestitial lung disease (Selva-O'Callaghan et al., 2005). The clinical 
presentation of interstitial lung disease includes progressive dyspnea on exertion, 
nonproductive cough, and basilar rales, and a rapidly progressive syndrome (Hamman-
Rich) may also occur. A rapidly progressive intestitial lung disease characterized by diffuse 
alveolar damage (DAD) often causes fatal respiratory failure. According to the 2002 
ATS/ERS consensus classification of IIPs (2002), several histologic patterns of intestitial lung 
disease are associated with PM-DM; nonspecific interstitial pneumonia (NSIP) is most often 
found and DAD, organizing pneumonia (OP), and usual interstitial pneumonia (UIP) are 
also present (Douglas et al., 2001, Kang et al., 2005, Marie et al., 2002, Tansey et al., 2004, 
Tazelaar et al., 1990). 
3.2 Treatment of interstitial lung disease associated with polymyositis and 
dermatomyositis 
Controlled trials on the effect of different treatments for intestitial lung disease in PM-DM 
have not been published. Thus, the optimal treatment program for the disease has not been 
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established. Available information on the efficacy of treatment is based on retrospective case 
collections or open trials. 
3.2.1 Glucocorticoids 
Prednisolone is considered the first-line drug for PM-DM patients with intestitial lung 
disease (Douglas et al., 2001, Grau et al., 1996, Hirakata & Nagai, 2000, Marie et al., 1998, 
Nawata et al., 1999, Oddis, 2000). It usually is started with 1 mg/kg/day or more for 4-6 
weeks. Another option is to start treatment with intravenous methylprednisolone (1g/day 
for 3 days, if necessary repeated after 1-2 weeks) and to continue treatment with oral 
prednisolone. Prednisolone in the 1mg/kg/day range seems effective in suppressing the 
PM-DM within a few weeks in most patients, but the lung disease usually is slower to 
respond to therapy than is the myositis and may require treatment over several months. 
High doses of prednisolone may lead to serious steroid side-effects, therefore, prednisolone 
is gradually tapered with careful monitoring of creatine kinase, chest radiographs, and 
pulmonary function. 
3.2.2 Immunosuppressive drugs 
Although most patients respond to some degree, corticosteroid treatment as a single agent is 
often not sufficient to obtain improvement of intestitial lung disease. Furthermore, the high 
doses required over a long period are often associated with severe side-effects and the 
addition of an immunosuppressive drugs becomes necessary as steroid sparing agents. 
Selection of immunosuppressive drugs remains empirical and depends on personal 
experience and the relative efficacy/safety ratio (Dalakas, 1994, Oddis, 2002). Favorable 
outcome with immunosuppressive therapy in patients who failed to respond to steroids 
alone has been reported previously (Nawata et al., 1999, Shinohara et al., 1997). However, a 
second immunosuppressive agent is added without waiting for a response to glucocorticoid 
therapy or a failure of tapering (Takada et al., 2007), in particular for patients with clinically 
amyopathic dermatomyositis because of the high frequency of progressive interstitial lung 
disease. 
Azathioprine (Douglas et al., 2001), or mycophenolate mofetil are often used and the 
comparative efficacy of these drugs is not known. Cyclophosphamide is an alternative if the 
patient has impending respiratory failure due to rapidly progressive interstitial lung disease 
with high dose glucocorticoids. Calcineurin inhibitors, cyclosporine and tacrolimus have 
been used in patients with inflammatory myopathy complicated by intestitial lung disease. 
In particular, cyclosporine has been reported to be effective to corticosteroid-resistant 
intestitial lung disease in PM-DM or clinically amyopathic dermatomyositis (Kameda et al., 
2005, Miyake et al., 2002). 
3.3 Prognostic factors associated with poor outcome of interstitial lung disease in 
polymyositis and dermatomyositis 
Various parameters related to intestitial lung disease poor outcome in PM-DM were 
identified as follows: DM subtype, Hamman-Rich type presentation, initial FVC less than 
60%, neutrophil alveolitis, histologic UIP, and features of clinically amyopathic 
dermatomyositis (Fujisawa et al., 2005, Kang et al., 2005, Marie et al., 2002). Schnabel et al. 
identified progressive disease, featuring ground-glass opacities on high resolution CT, and 
an inflammatory bronchoalveolar lavage (bronchoalveolar lavage) cell profile as indicators 
for intensive immunosuppressive therapy (Schnabel et al., 2003). Poor prognosis of patients 
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with UIP was confirmed in studies with lung histology (Marie et al., 2002, Tazelaar et al., 
1990). NSIP observed in PM-DM patients means the better survival compared with patients 
with idiopathic pulmonary fibrosis (Douglas et al., 2001) and mortality is similar to that seen 
in idiopathic NSIP (Tansey et al., 2004). In intestitial lung disease with clinically amyopathic 
dermatomyositis, although the most common finding is NSIP (Suda et al., 2006), the 
intestitial lung disease often takes an aggressive course even when the radiological and 
histological features are consistent with NSIP (Miyazaki et al., 2005). Tiju et al. reported that 
digital infarcts with microangiopathy may be a useful indicator for early intervention in 
intestitial lung disease associated with DM (Tjiu et al., 2004). 
4. Interstitial lung disease associated with clinically amyopathic 
dermatomyositis 
Patients with clinically amyopathic dermatomyositis sometimes develop rapidly 
progressive intestitial lung disease. It has been reported predominantly in Asia, including 
Japan, Hong Kong, and Taiwan (Lee et al., 2002, Mukae et al., 2009) and is often resistant to 
intensive therapy including high dose corticosteroids and immunosuppressive agents, 
resulting in fatal respiratory failure. 
4.1 A case with rapidly progressive interstitial lung disease in clinically amyopathic 
dermatomyositis 
A 46-year-old Japanese woman was admitted to a hospital because of eruption on arms to 
shoulders, erythema and swelling of hand joint, and dry cough for four weeks. The patient 
was diagnosed as dermatomyositis because of characteristic skin lesions. Chest radiograph 
and computed tomography on admission showed slight interstitial lung disease (Fig1A, D). 
Her respiratory function deteriorated in two weeks with progression of infiltrative shadow 
in chest radiograph and consolidation in particular around bronchovascular bundle in 
computed tomography (Fig1B, E). The patient was given methylprednisolone 1000mg 
intravenously daily for three days (pulse treatment) and transferred to our hospital. 
Blood gas analysis revealed PaO2 54.4 torr while she was breathing 3l/min oxygen by nasal 
plugs. Pulse treatment was followed by daily oral prednisolone 60 mg. Respiratory 
dysfunction became worse and finally fatal in two weeks after transfer in spite of repeated 
pulse treatment two more times (Fig1C). A second immunosuppressive agent was not 
added during hospitalization. 
4.2 A case with interstitial lung disease in clinically amyopathic dermatomyositis 
successfully treated by corticosteroid and cyclosporin 
A 31-year-old Japanese man developed bilateral hand erythema followed by fever 
(temperatures of more than 38°C) and hand and foot stiffness. The patient was admitted to a 
hospital suspected as dermatomyositis because of characteristic skin lesions. A chest 
radiograph and computed tomography on admission revealed reticular opacities in lower 
lobes (Fig2A, E). Interstitial lung disease progressed with remittent fever in three weeks. The 
patient was given methylprednisolone 1000mg intravenously daily for three days (pulse 
treatment) and transferred to our hospital. 
On examination, the temperature was 38.1°C, the blood pressure 118/78 torr, the pulse 80 
beats per minute, and the oxygen saturation 98% while he was breathing ambient air. The 
physical examination showed Gottron signs on fingers and fine crackles in bilateral back but  
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Fig. 1. Chest radiographs and computed tomography of a case with rapidly progressive 
interstitial lung disease associated with clinically amyopathic dermatomyositis. Very slight 
interstitial lung disease (A, D) deteriorated to be fatal in three months despite high dose 
corticosteroid treatment (B, C, E). 
no muscle weakness. Interstitial lung disease deteriorated on his chest radiograph and 
computed tomography (Fig2B, F). The patient was diagnosed as clinically amyopathic 
dermatomyositis because of slight elevation of creatinin kinase (551 IU/L), mild myopathic 
change in electromyography, and skin diseases. Pulse treatment was repeated two more 
times with daily oral predonisone 60 mg and cyclosporine of maximum dose 5 mg/kg/day. 
Although pneumomediastinum developed during tapering of prednisolone (Fig2C, G), 
interstitial lung disease gradually ameliorated with only linear opacities left in the lower 
lobes (Fig2D, H). 
4.3 A case with interstitial lung disease in clinically amyopathic dermatomyositis 
resistant to corticosteroid and cyclosporin 
A 56-year-old Japanese woman developed finger erythema. The erythema extended to her 
eyelids and then body in three weeks. Being suspected as dermatomyositis, she was referred 
and admitted to the hospital. On examination, the temperature was 37.0°C, the blood 
pressure 100/70 torr, the pulse 89 beats per minute, and the oxygen saturation 94% while 
she was breathing ambient air. The physical examination showed heliotrope erythema on 
eyelids, Gottron signs on fingers, and slight fine crackles in right back but no muscle 
weakness. A chest radiograph and computed tomography on admission revealed 
consolidation with reticular opacities in lower lobes (Fig3A, D). The patient was diagnosed 
as clinically amyopathic dermatomyositis because of slight elevation of creatine kinase (149 
IU/L), mild myopathic change in electromyography, and skin diseases. 
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Fig. 2. Chest radiographs and computed tomography of a case with interstitial lung disease 
associated with clinically amyopathic dermatomyositis successfully treated by corticosteroid 
and cyclosporin. Interstitial lung disease progressed (A, B, E, F) with pneumomediastinum 
complicated (C, G), however, was finally improved (D, H). 
The patient was given methylprednisolone 1000mg intravenously daily for three days (pulse 
treatment) followed by daily oral prednisolone 60 mg. Although respiratory functions with 
regard to AaDO2 and consolidation in lower lobes improved by prednisolone 60 mg for a 
month, reticular and ground-glass opacities appeared and progressed in upper lobes with 
worsening of AaDO2 when prednisolone was tapered to 50 mg/day (Fig3B, E). Cyclosporine 
of maximum dose 5 mg/kg/day and two more time pulse treatment were added with daily 
oral prednisolone 50 mg for another month. Interstitial lung disease gradually deteriorated 
in spite of the immunosuppressive therapy (Fig3C, F) and respiratory failure finally 
progressed to fatal in a week. 
5. Characteristics of patients with interstitial lung disease in polymyositis-
dermatomyositis resistant to prednisolone and cyclosporine 
Cyclosporine is sometimes effective to Japanese patients with corticosteroid-resistant 
intestitial lung disease in PM-DM or clinically amyopathic dermatomyositis (Kameda et al., 
2005, Miyake et al., 2002). However, the efficacy of cyclosporine remains limited and some 
patients still develop fatal respiratory failure. To clarify characteristics of fatal intestitial lung 
disease in PM-DM including clinically amyopathic dermatomyositis, we reviewed clinical 
records of PM-DM patients with intestitial lung disease. 
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Fig. 3. Chest radiographs and computed tomography of a case with interstitial lung disease 
associated with clinically amyopathic dermatomyositis resistant to treatment of 
corticosteroid and cyclosporin. Consolidation in lower lobes was improved by corticosteroid 
(A, B, D, E), but reticular and ground-glass opacities appeared and progressed in upper 
lobes to be fatal in spite of addition of cyclosporin (C, F). 
5.1 Study design 
Consecutive 26 PM-DM patients with intestitial lung disease underwent initial treatment in 
Niigata University Medical and Dental Hospital from January 1997 to June 2006. Diagnosis 
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of PM-DM was made according to the criteria of Bohan and Peter (Bohan & Peter, 1975). 
intestitial lung disease was diagnosed based on the presence of clinical symptoms, 
respiratory functions, and high-resolution computed tomography of the chest. Diagnosis of 
clinically amyopathic dermatomyositis was confirmed based on modified Euwer’s criteria 
(Euwer & Sontheimer, 1993) as follows: 1) characteristic dermatological manifestations of 
classic DM, including a heliotrope rash and Gottron’s papules; 2) no muscle weakness; and 
3) no increases in serum muscle enzymes during the observation period. All patients 
received oral prednisolone 1.0mg/kg/day for initial therapy. Corticosteroid pulse therapy 
(methyl prednisolone, 1000mg, 3days) was added when the worsening of respiratory 
function was observed under the treatment of 1.0mg/kg/day prednisolone. Effect of the 
treatment for intestitial lung disease was evaluated two weeks later by symptoms, blood gas 
analysis, chest X ray, and chest high resolution CT findings. We thought intestitial lung 
disease steroid-resistant when three of the above four findings were not improved and 
added cyclosporine to prednisolone keeping a trough level of 100 to 150ng/ml. Since 2002, 
cyclosporine dose has been increased to achieve a trough level of 300 ng/ml for up to 4 
weeks to expect the maximal immunosuppressive effect without adverse effects. Five of 26 
were excluded from this study because they had received cyclosporine before the evaluation 
of intestitial lung disease to have a sparing effect for high dose prednisolone. Finally 21 
patients with intestitial lung disease associated with PM-DM were enrolled in this study. 
Medical records were reviewed to obtain clinical data including history, treatment, and 
laboratory findings. 
5.2 Demographic data of patients 
Characteristics of 21 patients are shown in Table 1. Thirteen patients (61.9%) was effectively 
treated by corticosteroids alone. Cyclosporine was added to the other eight patients because 
of deterioration of intestitial lung disease even under steroid therapy. Out of these 8 steroid-
resistant cases, 4 patients (19.0%) improved by addition of cyclosporine, and the other 4 
patients (19.0%) showed no response to cyclosporine resulting in fatal respiratory failure. 
Finally, 17 patients survived and four died of respiratory failure due to progression of 
intestitial lung disease. All of the dead patients were diagnosed as clinically amyopathic 
dermatomyositis. 
 
Steroid-effective cases 
Steroid-resistant cases 
Cyclosporine-
effective 
Cyclosporine-
resistant 
Number of cases 13 (61.9%) 4 (19.0%) 4 (19.0%) 
Sex (M/F) 2/11 3/1 2/2 
Age (mean±SD) 54.5±14.3 52.0±17.7 58.8±5.1 
Diagnosis    
PM 0 1 0 
DM 9 2 0 
CADM 4 1 4 
Abbreviations: PM, polymyositis; DM, dermatomyositis; CADM, clinically amyopathic 
dermatomyositis 
Table 1. Demographic characteristics of PM-DM with intestitial lung disease patients. 
www.intechopen.com
 Interstitial Lung Disease Associated with Clinically Amyopathic Dermatomyositis 
 
99 
5.3 Summary of treatment 
Treatment in details is shown in Table 2. All the patients initially had 1mg/kg/day 
prednisolone. Steroid pulse therapy (methyl prednisolone 1000mg/day, three days) was 
given to 11 patients. Cyclosporine was added to 7 of 11 patients. Initial trough level of 
cyclosporine was usually maintained at 250 to 300 ng/ml to obtain maximal 
immunosuppressive effect. 
 
Steroid-effective 
cases (n=13) 
Steroid-resistant cases 
Cyclosporine-
effective (n=4) 
Cyclosporine-
resistant (n=4) 
Initial dose of PS 
(mg/day, mean±SD) 46.2±11.2 60.0±0.0 57.5±5.0 
Additional treatment    
m PSL pulse 4 0 0 
cyclosporine 0 1 0 
mPSL pulse, 
cyclosporine 
0 3 4 
cyclosporine trough level   
100~150ng/ml NA 1 0 
250~300ng/ml NA 3 4 
Abbreviations: PSL, prednisolone 
Table 2. Treatment of PM-DM with intestitial lung disease patients. 
 
Steroid-effective 
cases (n=13) 
Steroid-resistant cases 
Cyclosporine-effective 
(n=4) 
Cyclosporine-resistant 
(n=4) 
WBC (/l) 6292.3±1790.3 4 (19.0%) 4 (19.0%) 
CRP (mg/dl) 0.8±1.7 4.3±4.9* 1.7±1.8 
CK (IU/L) 1013.4±1272.5 2192.8±3084.4 158.5±54.2 
LDH (IU/L) 679.2±362.9 733.0±795.3 499.5±81.5 
AST (IU/L) 53.1±35.2 106.3±105.9 188.7±202.3 
ALT (IU/L) 38.4±28.5 65.0±48.0 157.8±203.8 
TP (g/dl) 6.8±0.6 6.5±0.4 6.7±0.4 
Alb (g/dl) 3.6±0.6 3.0±0.3 1 (25.0) 
ANA positive (%) 9 (69.2) 3 (75.0) 1 (25.0) 
Jo-1 positive (%) 2 (15.4) 2 (50.0) 1 (25.0) 
KL-6 (U/ml) 1127.8±454.1 769.3±570.9 797.0±180.5 
BGA (torr, room air)    
PaO2 81.8±8.8 82.7±14.1 63.4±8.6* 
PaCO2 41.5±3.8 36.2±4.1 37.1±1.2 
AaDO2 (torr) 16.4±9.0 22.1±18.6 40.3±8.0* 
*P<0.01 against steroid effective group. 
Table 3. Comparison of laboratory data on admission. 
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5.4 Laboratory findings 
Laboratory findings on admission are presented in Table 3. Serum CRP level of 
cyclosporine-effective group was higher than that of steroid-effective group. There were no 
significant differences in the levels of peripheral leukocyte count, serum CK, LDH, AST, 
ALT, total protein, albumin, and KL-6 among thee groups. PaO2 on admission was 
significantly decreased with an increase of AaDO2. in cyclosporine-resistant group. 
We often experience deterioration of intestitial lung disease associated with PM-DM when 
we perform laboratory, radiological, and neurological tests to make diagnosis of the disease. 
To evaluate progression of the disease during test period, we then compared changes in 
peripheral leukocyte count, serum CRP, CK, LDH, albumin, and AaDO2 from admission to 
administration of prednisolone. In cyclosporine-effective group, the level of serum CRP, CK, 
LDH, and AaDO2 significantly elevated during test period, while significant decrease of 
serum albumin and rapid progression of respiratory dysfunction indicated as AaDO2 were 
observed in cyclosporine-resistant group compared with steroid-effective group (Table 4). 
 
  Steroid-effective     Steroid-resistant cases 
      cases (n=13)         Cyclosporine-effective     Cyclosporine-resistant 
                       (n=3)                     (n=3) 
ΔWBC  -582.3±818.4             1335.0±3014.4  -516.7±692.1 
ΔCRP     0.4±0.9                     5.2±3.0*     0.7±0.8 
ΔCK    -67.5±466.8             2076.3±2008.9*    -3.0±71.0 
ΔLDH     -25.8±136.2               398.7±355.4*   -70.3±85.0§ 
ΔAlb     -0.2±0.4                   -0.5±0.1    -1.0±0.3*§ 
ΔAaDO2    -1.4±6.8                  22.0±5.0*    53.7±34.4* 
Δ=(value on admission)-(value on initial treatment) 
*P<0.05 against steroid-effective group, §P<0.05 against cyclosporine-effective group. 
Table 4. Changes of laboratory values from admission to initial treatment. 
5.5 Bronchoalveolar lavage analysis 
Bronchoalveolar lavage findings before treatment are available in 18 patients. Although 
there were no differences in total cell counts and frequency of alveolar macrophages, 
lymphocytes, and eosinophils in bronchoalveolar lavage fluid, frequency of neutrophils in 
cyclosporine-effective group was significantly higher than that in other two groups. In 
cyclosporine-resistant group, CD4/CD8 ratio was significantly higher compared with other 
groups (Table 5). 
 
        Steroid-effective  Steroid-resistant cases 
               cases (n=12) Cyclosporine-effective    Cyclosporine-resistant 
                  (n=4)       (n=4) 
    TCC (×105/ml)    3.2±1.4                         5.5±2.8   5.6±2.4 
           AM (%)  51.2±20.6                      49.5±31.2               61.1±23.5 
          Lym (%)  41.0±22.5                      38.2±31.1               35.2±21.8 
          Neut (%)     4.2±5.1                       11.2±6.1**§   1.6±2.6 
            Eo (%)    3.6±6.0                         1.4±0.9   0.6±0.5 
      CD4/CD8 ratio 0.44±0.53                       0.70±0.6   1.9±0.9* 
*P<0.01 against steroid-effective group, **P<0.05 against steroid-effective group, §P<0.05 against 
cyclosporine-resistant group. 
Table 5. Comparison of bronchoalveolar lavage findings. 
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5.6 Characteristics of patients with interstitial lung disease in polymyositis-
dermatomyositis resistant to prednisolone and cyclosporine 
Cyclosporin binds to cyclophilin, then the complex inhibits calcineurin phosphatase and T-
cell activation (Clipstone & Crabtree, 1992). Because activated T lymphocytes, in particular 
CD8+ T cells, may play essential roles in intestitial lung disease associated with PM-DM 
(Enomoto et al., 2003, Kourakata et al., 1999, Kurasawa et al., 2002), immunosuppressive 
therapy targeting CD8+ cells should be reasonable. However, CD4/8 ratio in 
bronchoalveolar lavage fluid was significantly increased in cyclosporine-resistant cases 
compared to alive ones. Suda et al. also described that the ratio of CD4/8 lymphocytes was 
higher in acute/subacute intestitial lung disease than chronic intestitial lung disease in 
clinically amyopathic dermatomyositis, but the difference was not statistically significant 
(Suda et al., 2006). Increased CD4/8 ratio in bronchoalveolar lavage fluid suggests that CD8+ 
T cells may not be major pulmonary inflammatory cells causing lung injury in PM-DM. 
In this study, all of the cyclosporine-resistant cases were diagnosed as clinically amyopathic 
dermatomyositis and died of respiratory failure. While, five of nine patients with intestitial 
lung disease in clinically amyopathic dermatomyositis survived without progression of 
respiratory failure. Cottin et al. also described a benign form of intestitial lung disease in 
clinically amyopathic dermatomyositis (Cottin et al., 2003). Clinically amyopathic 
dermatomyositis with fatal interstitial lung disease may be a distinct clinical entity with 
unique clinical features. 
5.7 Salvage therapy to interstitial lung disease in polymyositis-dermatomyositis 
For patients with progressive intestitial lung disease in spite of the combination of 
glucocorticoids and a second agent, a third immunosuppressive agent may be added. 
High dose glucocorticoids, monthly intravenous cyclophosphamide, and cyclosporine 
may be used in combination for patients with intestitial lung disease in clinically 
amyopathic dermatomyositis, even when the intestitial lung disease is still mild. Primary 
intensive approach by starting immunosuppressive agents simultaneously with 
corticosteroids was associated with better survival than step-up approach by adding them 
sequentially in initial treatment for active intestitial lung disease in PM-DM (Takada et al., 
2007). 
In spite of the combination therapies with glucocorticoids and immunosuppressive agents, 
respiratory dysfunction of PM-DM patients with intestitial lung disease sometimes 
progresses. Although options for salvage therapy including rituximab, intravenous immune 
globulin, and lung transplantation are reported (Labirua & Lundberg, 2010, Shoji et al., 2010, 
Suzuki et al., 2009), the effects of these therapies are still unknown or limited. Recently, a 
case with rapidly progressive interstitial pneumonia associated with clinically amyopathic 
dermatomyositis successfully treated with polymyxin B-immobilized fiber column (PMX) 
hemoperfusion was reported (Kakugawa et al., 2008). PMX might improve oxygenation in 
patients with acute lung injury/ acute respiratory distress syndrome or with acute 
exacerbation of idiopathic pulmonary fibrosis (Kushi et al., 2005, Seo et al., 2006). This could 
be another option for intestitial lung disease in clinically amyopathic dermatomyositis 
resistant to immunosuppressive treatment. 
6. Myositis-associated autoantibodies 
About 30 percent of patients with DM or PM have myositis-associated autoantibodies with 
clinical findings of the relatively acute disease onset, constitutional symptoms, Raynaud's 
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phenomenon, mechanic's hands, arthritis, and interstitial lung disease. Three major 
categories of myositis-specific autoantibodies are reported: anti-aminoacyl-tRNA synthetase 
antibodies, anti-SRP antibodies, and anti-Mi-2 antibodies. The presence of individual 
myositis antibodies may play a role in determining the disease manifestations. 
6.1 Anti-aminoacyl-tRNA synthetase antibodies 
A group of myositis-associated autoantibodies is strongly linked to the development of 
intestitial lung disease (Grau et al., 1996, Targoff, 2008). These antibodies are directed 
against aminoacyl-tRNA synthetase (aaRS). The most common, anti-aaRS specific for 
histidine (anti-Jo-1), is found in approximately 29% of patients with DM and is found even 
more frequently in cases with intestitial lung disease (Botha & Carney, 1999, Climent-
Albaladejo et al., 2002). Others have been labeled anti-PL-7 (for threonine), anti-PL-12 
(alanine), anti-EJ (glycine), anti-KS (asparagine), anti-OJ (isoleucine), and anti-Zo 
(phenylalanine) (Betteridge et al., 2007). Each of these antibodies has been associated with 
antisynthetase syndrome marked by a high frequency of intestitial lung disease compared 
with PM-DM without such antibodies (Targoff, 2008). Selva-O'Callaghan et al. reported that 
anti-aaRS negative patients with acute interstitial lung disease and pneumomediastinum 
had an unfavorable prognosis (Selva-O'Callaghan et al., 2005). 
6.2 Anti-SRP and anti-Mi-2 antibodies 
The signal recognition particle (SRP) is involved in the translocation of newly synthesized 
proteins into the endoplasmic reticulum. Anti-SRP antibodies are present in 4 to 6 percent of 
patients with acquired inflammatory and/or necrotizing myopathies (Hengstman et al., 
2006). They are associated with aggressive disease with heart and lung involvement and 
resistance to high-dose glucocorticoids and adjunct immunosuppressive agents (Arlet et al., 
2006). Anti-Mi-2 antibodies are directed against a helicase involved in transcriptional 
activation. They are present in 10– 30% of patients with DM (Ghirardello et al., 2005) and 
associated with severer cutaneous manifestations but a better response to steroid therapy 
(Hengstman et al., 2006). 
6.3 Anti-CADM-140 antibody 
A novel autoantibody associated with PM-DM was identified by screening with 
immunoprecipitation in 298 serum samples from patients with various connective tissue 
diseases or idiopathic pulmonary fibrosis. Eight out of 298 sera recognized a polypeptide of 
approximately 140 kd by immunoprecipitation and immunoblotting. Interestingly, all 8 
patients with the antibodies had clinically amyopathic dermatomyositis and rapidly 
progressive interstitial lung disease with significantly higher frequency (Sato et al., 2005). 
Furthermore, the antibody, termed “anti-CADM-140 antibody＂ recognizes an antigen 
identified to be an RNA helicase encoded by melanoma differentiation-associated gene 5 
(MDA-5) (Sato et al., 2009). RNA helicase encoded by MDA-5 is a critical molecule involved 
in the innate immune defense against viruses and viral infection. Although a role of anti-
CADM-140 antibody in developing rapidly progressive interstitial lung disease in clinically 
amyopathic dermatomyositis is still unknown, this may provide a clue about the 
pathogenesis of the disease and lead to novel effective treatment for the disease. 
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6.4 A case with clinically amyopathic dermatomyositis with anti-CADM-140 antibody 
positive 
A 45-year-old Japanese woman had complained of itchy erythema, finger joint pain, 
Raynaud phenomenon, and facial rush for 6 months. She was admitted to the hospital being 
suspected as dermatomyositis because of skin lesions, but not diagnosed definitely. Chest 
radiograph and computed tomography showed very slight interstitial lung disease (Fig4A, 
B). Although daily oral prednisolone 20mg relieved her symptoms, her skin lesions and joint 
pain recurred during prednisolone tapering in 10 months. 
 
 
          A            B 
 
           C            D 
Fig. 4. Chest computed tomography of a case with interstitial lung disease associated with 
clinically amyopathic dermatomyositis with anti-CADM-140 antibody positive. Chest 
computed tomography on the first admission (A, B) and the second admission about one 
year later (C, D) indicated progression of interstitial lung disease in spite of daily oral 
prednisolone 20mg. 
The patient was admitted to the hospital again. On examination, the temperature was 
37.1°C, the blood pressure 101/74 torr, the pulse 89 beats per minute, and the oxygen 
saturation 98% while she was breathing ambient air. The physical examination showed 
Gottron signs on fingers, hand skin sclerosis, and Raynaud phenomenon, but no fine 
crackles auscultated or muscle weakness. Chest computed tomography revealed marked 
reticular and ground-glass opacities in lower lobes (Fig4C, D). The patient was suspected as 
clinically amyopathic dermatomyositis because of characteristic skin diseases. Surgical lung 
biopsy was performed to pathologically evaluate lung diseases. Specimens from right S2 
segment contained fibrotic lesions distributed at subpleural and perivenous area and wide 
fibrosis extending from subpleural area with alveolar collapse (Fig5A, original 
magnification, x 5). Mild to moderate lymphocyte infiltration with lymph follicles in the 
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   A            B          C 
 
   D            E              F 
Fig. 5. Light microscopic findings of the lung specimen from a case with anti-CADM-140 
antibody. Patchy fibrosing lesions were seen in the upper lobe specimens (A, B, C), while 
fibrotic nonspecific interstitial pneumonia (fNSIP) pattern was recognized in the specimens 
from lower lobe (D, E, F). 
 
        A                B 
Fig. 6. Chest computed tomography of a case with interstitial lung disease associated with 
clinically amyopathic dermatomyositis with anti-CADM-140 antibody. Chest computed 
tomography on admission (A) and in treatment (B) were shown. Interstitial lung disease 
improved by daily intravenous methylprednisolone 500mg three days followed by daily 
oral prednisolone and cyclosporine for 14 days. 
fibrotic lesions and ring fibrosis connecting alveolar orifices at the rim of collapsing fibrosis 
were seen (Fig5B, C, original magnification, x 20). Specimens from right S10 segment 
revealed homogenously distributed fibrotic lesions (Fig5D, original magnification, x 5). 
Alveolar walls were thickened by fibrosis with simplified alveolar construction and 
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polypoid tissue protruding into alveolar spaces was also seen (Fig5E, F, original 
magnification, x 20). 
The patient was given methylprednisolone 500mg intravenously daily for three days 
followed by daily oral prednisolone 40 mg and cyclosporine of 100 to 150 mg /day. Anti-
CADM-140 antibody was proven to be positive during the treatment of prednisolone and 
cyclosporine. Interstitial lung disease gradually ameliorated by prednisolone (Fig6A, B). 
7. Conclusion 
Clinically amyopathic dermatomyositis is a condition which includes the characteristic rash 
but little or no evidence of myositis. Patients with PM-DM, in particular clinically 
amyopathic dermatomyositis sometimes develop rapidly progressive intestitial lung 
disease. The disease is often resistant to intensive therapy including high dose 
corticosteroids and immunosuppressive agents, resulting in fatal respiratory failure. 
Although cyclophosphamide, cyclosporin, and tacrolimus were reported to be effective in 
treatment of refractory intestitial lung disease in PM-DM, the effect of these drugs were still 
limited. Our retrospective study suggested that features of glucocorticoid/cyclosporin-
resistant intestitial lung disease associated with PM-DM might be 1) a subtype of clinically 
amyopathic dermatomyositis, 2) hypoxemia on admission and further progression of 
respiratory dysfunction, 3) progression of hypoalbuminemia before treatment, and 4) 
elevated CD4/8 ratio in bronchoalveolar lavage fluid. 
A variety of serum autoantibodies are specifically detected in patients with PM-DM, 
including antibodies reactive with aminoacyl-transfer RNA synthetase. These 
autoantibodies are associated with distinct clinical subsets of PM-DM. Recently a novel PM-
DM associated autoantibody, termed “anti-CADM-140 antibody＂ is reported. This 
antibody is strongly associated with clinically amyopathic dermatomyositis, in particular 
rapidly progressive intestitial lung disease complicated. This may provide a clue about the 
pathogenesis of the disease and lead to novel effective treatment for the disease. 
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The term "myositis" covers a variety of disorders often designated "idiopathic inflammatory myopathies".
Although they are rather rare compared to other rheumatic diseases, they often cause severe disability and
not infrequently increased mortality. The additional involvement of important internal organs such as the heart
and lungs, is not uncommon. Thus, there is a great need for a better understanding of the etiopathogenesis of
myositis, which may lead to improved treatment and care for these patients. Major advances regarding
research and medical treatment have been made during recent years. Of particular importance is the
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clinical disease entities. A wide range of aspects of myopathies is covered in the book presented by highly
qualified authors, all internationally known for their expertice on inflammatory muscle diseases. The book
covers diagnostic, pathological, immunological and therapeutic aspects of myositis.
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